课题基金 / 基金详情

Molecular mechanisms underlying cardiac sodium channelopathy

Molecular mechanisms underlying cardiac sodium channelopathy
心脏钠离子通道病的分子机制
批准号:
9974589
负责人:
Masayuki Yazawa
金额:
$39.66万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-07-01 至 2022-06-30

项目摘要

项目成果

Masayuki Yazawa的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary: The cardiac voltage-gated sodium channel, NaV1.5, plays an important role in cardiac function. Genetic mutations in NaV1.5 are known to be associated with various cardiac arrhythmias including long QT syndrome. Our preliminary results suggested that NaV1.5 channel is regulated by cyclin-dependent kinase 5 (CDK5) and that CDK5 and NaV1.5 channel are involved in cardiac arrhythmias caused by genetic mutations in the CACNA1C calcium channel and MYH7 myofilament genes. The primary goal of this study is to unveil the molecular mechanisms of cardiac NaV1.5 channel regulation and to elucidate the pathophysiological mechanisms underlying cardiac arrhythmias associated with sodium channelopathy. Aim 1 is to examine how CDK5 regulates NaV1.5 channels using human and mouse models with electrophysiological recordings. Aim 2 is to elucidate how cardiac sodium channel dysfunction results from the cardiac calcium channel mutants in long QT syndrome type 8. Aim 3 is to test the hypothesis that CDK5 and NaV1.5 abnormalities are involved in familial hypertrophic cardiomyopathy and arrhythmias that are caused by a familial MYH7 mutation. The approaches of our study would provide new insights into the molecular basis of cardiac sodium channel regulation and the pathophysiological mechanisms underlying cardiac arrhythmias with sodium channelopathy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Therapeutics for Timothy Syndrome and Related Cardiac Channelopathy
Novel Therapeutics for Long QT Syndrome
Novel Therapeutics for Long QT Syndrome
Molecular mechanisms underlying cardiac sodium channelopathy
海外基金